Vijaya Diagnostics Q4 Results Review - Renewed Push For Growth; Upgrade To Add: Yes Securities

"NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Yes Securities Report.Vijaya Diagnostics Ltd.'s management appeared upbeat on centre addition and indicated opening of ~10 hubs in two years at a capex of Rs 2-2.2 billion which appears an increase over previously outlined expansion. Pune would be the focus area as company attempts to create Hyderabad type of network with addition of five hubs over next two years. Q4 footfall growth excluding PH at ~15% is an affirmation of healthy underlying trend in volumes especially in core Hyderabad market which is growing in early double digit. Capex of Rs 1-1.1 billion in FY25 and FY26 each is well within the estimated Rs 1.8-1.9 billion in operating cash thrown in each of those two years leaving room for further expansion. We reckon capex has been increased by Rs 400 million over next two years with revenue impact seen from FY26 onwards; accordingly, we have raised FY26 volume growth by ~3% ex-PH along with Rs 700 million PH revenues (currently Rs 450 million annualised) leading to a raise in EPS estimate by 14%. Anticipating a faster growth ambition, we raise target PE multiple to 40 times (slight premium to Dr. Lal Pathlabs Ltd. /Metropolis) and upgrade to Add with revised target price Rs 800 (earlier Rs 610)..Click on the attachment to read the full report:.Alembic Pharma Q4 Results Review - New Launches In U.S., Capacity Utilisation To Drive Growth: Nirmal Bang.DISCLAIMERThis report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit..Users have no license to copy, modify, or distribute the content without permission of the Original Owner."

Vijaya Diagnostics Q4 Results Review - Renewed Push For Growth; Upgrade To Add: Yes Securities

Revenue beat as standalone volume growth of 14.7% supports 18.5% increase in sales

NDTV Profit

NDTV Profit

Follow Us

DOWNLOAD THE APP

Vijaya Diagnostics Q4 Results Review - Renewed Push For Growth; Upgrade To Add: Yes Securities

Revenue beat as standalone volume growth of 14.7% supports 18.5% increase in sales

Choose a plan

Follow Us

DOWNLOAD THE APP